Autoimmune Blistering Diseases in the Elderly: Clinical Presentations and Management (Q38980040)

8 September 2017

1 reference

title

Autoimmune Blistering Diseases in the Elderly: Clinical Presentations and Management (English)

1 reference

8 September 2017

Minhee Kim

1 reference

8 September 2017

Luca Borradori

series ordinal

1 reference

8 September 2017

Dédée F Murrell

series ordinal

1 reference

8 September 2017

publication date

13 October 2016

1 reference

8 September 2017

1 reference

8 September 2017

1 reference

8 September 2017

1 reference

8 September 2017

page(s)

711-723

1 reference

Clinical implications of aging skin: cutaneous disorders in the elderly

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Management of autoimmune skin disorders in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Laboratory diagnosis of paraneoplastic pemphigus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Increased risk of bullous pemphigoid in male and very old patients: A population-based study on incidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Mortality of bullous pemphigoid in Switzerland: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Prodromal bullous pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Drug‐induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase‐IV inhibitors plus metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Dipeptidyl Peptidase-4 Inhibitors Cause Bullous Pemphigoid in Diabetic Patients: Report of Two Cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

A comparison of oral and topical corticosteroids in patients with bullous pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Corticosteroid use in autoimmune blistering diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Interventions for bullous pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

A randomized controlled trial to compare the safety and effectiveness of doxycycline (200 mg daily) with oral prednisolone (0.5 mg kg(-1) daily) for initial treatment of bullous pemphigoid: a protocol for the Bullous Pemphigoid Steroids and Tetracyc

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Intravenous immune globulin and thromboembolic adverse events: A systematic review and meta-analysis of RCTs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Sustained clinical response to rituximab in a case of life-threatening overlap subepidermal autoimmune blistering disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Omalizumab therapy for bullous pemphigoid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Mucous membrane pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Update on mucous membrane pemphigoid: a heterogeneous immune-mediated subepithelial blistering entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Anti-epiligrin cicatricial pemphigoid and relative risk for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

A case of anti-epiligrin cicatricial pemphigoid associated with lung carcinoma and severe laryngeal stenosis: review of Japanese cases and evaluation of risk for internal malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Prevalence and clinical significance of anti-laminin 332 autoantibodies detected by a novel enzyme-linked immunosorbent assay in mucous membrane pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Ocular Cicatricial Pemphigoid: A Review of Clinical Features, Immunopathology, Differential Diagnosis, and Current Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

A prospective study of upper aerodigestive tract manifestations of mucous membrane pemphigoid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Epidermolysis bullosa acquisita

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Systemic minocycline as a therapeutic option in predominantly oral mucous membrane pemphigoid: a cautionary report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Oral cyclophosphamide without corticosteroids to treat mucous membrane pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Rituximab for patients with refractory mucous membrane pemphigoid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Mycophenolate mofetil for ocular inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Epidermolysis Bullosa Acquisita: A Retrospective Clinical Analysis of 30 Cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Epidermolysis bullosa acquisita. Report of three cases and review of all published cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Colchicine for epidermolysis bullosa acquisita

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Cyclosporine controls epidermolysis bullosa acquisita co-occurring with acquired factor VIII deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Prognostic factors of paraneoplastic pemphigus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Constrictive bronchiolitis associated with paraneoplastic autoimmune multi-organ syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Paraneoplastic pemphigus in association with Castleman's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Improved outcomes after complete resection of underlying tumors for patients with paraneoplastic pemphigus: a single-center experience of 22 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

The mechanism of respiratory failure in paraneoplastic pemphigus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Alemtuzumab-induced remission of both severe paraneoplastic pemphigus and leukaemic bone marrow infiltration in a case of treatment-resistant B-cell chronic lymphocytic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-016-0402-1

Clinical and immunopathological spectrum of paraneoplastic pemphigus

21 January 2018

1 reference

12 December 2020

Pemphigus vulgaris is the most common autoimmune bullous disease in Northwestern Romania

1 reference

12 December 2020

Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept

1 reference

12 December 2020

Treatment of epidermolysis bullosa acquisita with cyclosporine

1 reference

12 December 2020

[Value of colchicine in treating acquired epidermolysis bullosa]

1 reference

12 December 2020

Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus

1 reference

12 December 2020

Cicatricial pemphigoid

1 reference

12 December 2020

Oral mucous membrane pemphigoid: complete response to topical tacrolimus

1 reference

12 December 2020

Paraneoplastic pemphigus

1 reference

12 December 2020

Successful treatment of bullous pemphigoid with omalizumab

1 reference

12 December 2020

Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus

1 reference

12 December 2020

Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus.

1 reference

12 December 2020

1 reference

12 December 2020

Treatment of epidermolysis bullosa acquisita with intravenous immunoglobulin in patients non‐responsive to conventional therapy: clinical outcome and post‐treatment long‐term follow‐up

1 reference

12 December 2020

Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group

1 reference

12 December 2020

Treatment of ocular cicatricial pemphigoid with the tumour necrosis factor alpha antagonist etanercept

1 reference

12 December 2020

Neurological disorders in patients with bullous pemphigoid

1 reference

12 December 2020

Recalcitrant cicatricial pemphigoid treated with the anti-TNF-alpha agent etanercept.

1 reference

12 December 2020

Incidence and Mortality of Bullous Pemphigoid in France

1 reference

12 December 2020

Mucous membrane pemphigoid: clinical aspects, immunopathological features and therapy

1 reference

12 December 2020

Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany

1 reference

12 December 2020

U-serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases

1 reference

12 December 2020

Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients

1 reference

12 December 2020

Toward a practical renaming of bullous pemphigoid and all its variants: cutaneous pemphigoid

1 reference

12 December 2020

Paraneoplastic pemphigus or paraneoplastic autoimmune multiorgan syndrome. Report of 2 cases in children and a review of the literature

1 reference

12 December 2020

A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors

1 reference

12 December 2020

Direct immunofluorescence studies of sodium chloride-separated skin in the differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita

1 reference

12 December 2020

Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita

1 reference

12 December 2020

Epidermolysis bullosa acquisita: literature review

1 reference

12 December 2020

Childhood epidermolysis bullosa acquisita. Report of three cases and review of literature

1 reference

12 December 2020

Treatment of cicatricial pemphigoid with pulse intravenous cyclophosphamide

1 reference

12 December 2020

Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients

1 reference

12 December 2020

Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid

1 reference

12 December 2020

Cicatricial pemphigoid-induced phimosis

1 reference

12 December 2020

Paraneoplastic pemphigus

1 reference

12 December 2020

Acquired epidermolysis bullosa with the clinical feature of Brunsting-Perry cicatricial bullous pemphigoid

1 reference

12 December 2020

Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany

1 reference

12 December 2020

Anti-epiligrin cicatricial pemphigoid: clinical findings, immunopathogenesis, and significant associations

1 reference

12 December 2020

Epidermolysis bullosa acquisita with ultraviolet radiationsensitivity

1 reference

12 December 2020

Clinical phenotype and anti-desmoglein autoantibody profile in paraneoplastic pemphigus

1 reference

12 December 2020

The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan

1 reference

12 December 2020

Epidermolysis bullosa acquisita, a rare late complication of allogeneic bone marrow transplantation?

1 reference

12 December 2020

Antigen specificity in subsets of mucous membrane pemphigoid

1 reference

12 December 2020

Epidermolysis bullosa acquisita in childhood

1 reference

12 December 2020

Rituximab for treatment-refractory pemphigus and pemphigoid: A case series of 17 patients

1 reference

12 December 2020

Successful biologic treatment of ocular mucous membrane pemphigoid with anti-TNF-alpha

1 reference

12 December 2020

Epidermolysis bullosa acquisita exacerbated by systemic estrogen and progesterone treatment and pregnancy

1 reference

12 December 2020

[Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day. A multicenter randomized study]

1 reference

12 December 2020

Nicotinamide and tetracycline therapy of bullous pemphigoid.

1 reference

12 December 2020

10.1007/S40266-016-0402-1

Identifiers

DOI

1 reference

8 September 2017

1 reference